author-photo

Steven G. Wong

University of California, Los Angeles

22

Papers

16855

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
The TNT protocol: A phase II study using talimogene laherparepvec (TVEC), nivolumab (N) and trabectedin (T) as first, second/third line therapy for advanced sarcoma, including desmoid tumor and chordoma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase I/II investigation of nivolumab and ABI-009 (nab-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing sarcoma: Preliminary efficacy and safety results.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Initial results of a phase III investigation of safety/efficacy of nivolumab and ABI-009 (nab-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing sarcoma.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Lack of cardiac toxicity in patients treated with aldoxrubicin with doxorubicin equivalent doses beyond 1000mg/m2.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification

2016 Case Reports in Oncology
Show All
- Source
- Cite
- Save
Citations (8)
A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

2014
Show All
- Source
- Cite
- Save
Citations (36)